Glutamate dependent NMDA receptor 2D is a novel angiogenic tumour endothelial marker in colorectal cancer

Oncotarget

Volumn 7, Issue 15, 2016, Pages 20440-20454

  Ferguson, Henry J M ^a,b   Wragg, Joseph W ^a   Ward, Stephen ^b   Heath, Victoria L ^a   Ismail, Tariq ^b   Bicknell, Roy ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Active immunotherapy; Colorectal cancer; GRIN2D; Tumour endothelial marker; Vaccination

Indexed keywords

INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2D; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; GRIN2D PROTEIN, HUMAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; EXTRACELLULAR MATRIX; FNDC1 GENE; GENE IDENTIFICATION; GENETIC SELECTION; GPR4 GENE; GRIN2D GENE; HUMAN; HUMAN CELL; KCNJ8 GENE; MARKER GENE; MOUSE; NONHUMAN; OR51E1 GENE; PROTEIN EXPRESSION; PROTEIN TARGETING; RGS5 GENE; STRA6 GENE; TGM2 GENE; ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG SCREENING; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR CELL CULTURE; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MICE, INBRED BALB C; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; RECEPTORS, N-METHYL-D-ASPARTATE; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964786056     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7812     Document Type: Article

References (53)

1. Stewart BW, Wild CP. World Cancer Report. World Health Organisation. 2014.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-30
3. Dukes CE, Bussey HJ. The spread of rectal cancer and its effect on prognosis. British Journal of Cancer. 1958;12:309-20.
4. Quirke P, Durdey P, Dixon MF, Williams NS. Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet. 1986;2:996-9.
5. Tebbutt NC, Cattell E, Midgley R, Cunningham D, Kerr D. Systemic treatment of colorectal cancer. Eur J Cancer. 2002;38:1000-15.
6. Lokich J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology (Williston Park, NY). 1998;12:19-22.
7. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol. 2005;23:4553-60.
8. Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res. 2006;12:3064-9.
9. Cersosimo RJ. Management of advanced colorectal cancer, Part 2. American Journal of Health-System Pharmacy. 2013;70:491-506.
10. Ferguson HJM, Wragg J, Ismail T, Bicknell R. Vaccination against tumour blood vessels in colorectal cancer. European Journal of Surgical Oncology. 2014;40:133-6.
11. Mosolits S, Ullenhag G, Mellstedt H. Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results. Ann Oncol. 2005;16:847-62.
12. Huminiecki L, Gorn M, Suchting S, Poulsom R, Bicknell R. Magic roundabout is a new member of the roundabout receptor family that is endothelial specific and expressed at sites of active angiogenesis. Genomics. 2002;79:547-52.
13. Mura M, Swain RK, Zhuang X, Vorschmitt H, Reynolds G, Durant S, Beesley JF, Herbert JM, Sheldon H, Andre M, Sanderson S, Glen K, Luu NT, et al. Identification and angiogenic role of the novel tumor endothelial marker CLEC14A. Oncogene. 2011;31:293-305.
14. Zhuang X, Ahmed F, Zhang Y, Ferguson HJ, Steele JC, Steven NM, Nagy Z, Heath VL, Toellner KM, Bicknell R. Robo4 vaccines induce antibodies that retard tumor growth. Angiogenesis. 2015;18:83-95.
15. Wragg JW, Bicknell R. Next-generation transcriptomic analysis in cancer vascular research. European Pharmaceutical Review. 2015;4:10-3.
16. Siegler Retchless B, Gao W, Johnson JW. A single GluN2 subunit residue controls NMDA receptor channel properties via intersubunit interaction. Nat Neurosci. 2012;15:406-13-S1-2.
17. Sobolevsky AI, Rosconi MP, Gouaux E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature. 2009;462:745-56.
18. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8:34-47.
19. Deenick EK, Hasbold J, Hodgkin PD. Decision criteria for resolving isotype switching conflicts by B cells. Eur J Immunol. 2005;35:2949-55.
20. Hollmann M. Structure of Ionotropic Glutamate Receptors. Springer-Verlag Berlin Heidelberg. 1999;141:3-98.
21. Ikeda K, Araki K, Takayama C, Inoue Y, Yagi T, Aizawa S, Mishina M. Reduced spontaneous activity of mice defective in the epsilon 4 subunit of the NMDA receptor channel. Brain Res Mol Brain Res. 1995;33:61-71.
22. Miyamoto Y, Yamada K, Noda Y, Mori H, Mishina M, Nabeshima T. Lower sensitivity to stress and altered monoaminergic neuronal function in mice lacking the NMDA receptor epsilon 4 subunit. J Neurosci. 2002;22:2335-42.
23. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37:4-15.
24. Gualandris A, Noghero A, Geuna M, Arese M, Valdembri D, Serini G, Bussolino F. Microenvironment drives the endothelial or neural fate of differentiating embryonic stem cells coexpressing neuropilin-1 and Flk-1. FASEB J. 2008;23:68-78.
25. Hamdollah Zadeh MA, Glass CA, Magnussen A, Hancox JC, Bates DO. VEGF-mediated elevated intracellular calcium and angiogenesis in human microvascular endothelial cells in vitro are inhibited by dominant negative TRPC6. Microcirculation. 2008;15:605-14.
26. Fiorio Pla A, Grange C, Antoniotti S, Tomatis C, Merlino A, Bussolati B, Munaron L. Arachidonic acid-induced Ca2+ entry is involved in early steps of tumor angiogenesis. Mol Cancer Res. 2008;6:535-45.
27. Munaron L, Scianna M. Multilevel complexity of calcium signaling: Modeling angiogenesis. World J Biol Chem. 2012;3:121-6.
28. Wyllie DJ, Béhé P, Colquhoun D. Single-channel activations and concentration jumps: comparison of recombinant NR1a/NR2A and NR1a/NR2D NMDA receptors. J Physiol. 1998;510:1-18.
29. Cull-Candy S, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol. 2001;11:327-35.
30. Munaron L, Tomatis C, Fiorio Pla A. The secret marriage between calcium and tumor angiogenesis. Technol Cancer Res Treat. 2008;7:335-9.
31. Stepulak A, Luksch H, Gebhardt C, Uckermann O, Marzahn J, Sifringer M, Rzeski W, Staufner C, Brocke KS, Turski L, Ikonomidou C. Expression of glutamate receptor subunits in human cancers. Histochem Cell Biol. 2009;132:435-45.
32. Herner A, Sauliunaite D, Michalski CW, Erkan M, De Oliveira T, Abiatari I, Kong B, Esposito I, Friess H, Kleeff J. Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling. Int J Cancer. 2011;129:2349-59.
33. Koochekpour S. Glutamate, a metabolic biomarker of aggressiveness and a potential therapeutic target for prostate cancer. Asian J Androl. 2013;15:212-3.
34. Stepulak A, Rola R, Polberg K, Ikonomidou C. Glutamate and its receptors in cancer. J Neural Transm. 2014;121:933-44.
35. Markman B, Ramos FJ, Capdevila J, Tabernero J. EGFR and KRAS in colorectal cancer. Adv Clin Chem. 2010;51:71-119.
36. Zhou Q, Nicholas Verne G. NMDA Receptors and Colitis: Basic Science and Clinical Implications. Rev Analg. 2008;10:33-43.
37. Lampson LA. Monoclonal antibodies in neurooncology: Getting past the blood-brain barrier. MAbs. 2011;3:153-60.
38. Mege D, Ouaissi M, Fuks D, Metellus P, Peltier J, Dufour H, Regimbeau JM, Dahan L, Sielezneff I, Sastre B. Patients with brain metastases from colorectal cancer are not condemned. Anticancer Res. 2013;33:5645-8.
39. Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E, Mangala LS, Wu SY, Pradeep S, Li D, Han C, Dalton H, Lopez-Bernstein G, et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013;24:229-41.
40. Pircher A, Fiegl M, Untergasser G, Heidegger I, Medinger M, Kern J, Hilbe W.Favorable prognosis of operable nonsmall cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs). Lung Cancer. 2013;81:252-8.
41. Jones CA, Nishiya N, London NR, Zhu W, Sorensen LK, Chan AC, Lim CJ, Chen H, Zhang Q, Schultz PG, Hayallah AM, Thomas KR, Famulok M, et al. Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nature. 2009;11:1325-31.
42. Palumbo A, Hauler F, Dziunycz P, Schwager K, Soltermann A, Pretto F, Alonso C, Hofbauer GF, Boyle RW, Neri D. A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. British Journal of Cancer. 2011;104:1106-15.
43. Chinnasamy D, Yu Z, Theoret MR, Zhao Y, Shrimali RK, Morgan RA, Feldman SA, Restifo NP, Rosenberg SA. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J Clin Invest. 2010;120:3953-68.
44. Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther. 2014;22:1018-28.
45. Huijbers EJM, Femel J, Andersson K, Björkelund H, Hellman L, Olsson A-K. The non-toxic and biodegradable adjuvant Montanide ISA 720/CpG can replace Freund's in a cancer vaccine targeting ED-B-a prerequisite for clinical development. Vaccine. 2012;30:225-30.
46. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Annals of Oncology. 2012;23 Suppl 8:viii6-9.
47. Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335:2-13.
48. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8:59-73.
49. Brack A, Rittner HL, Stein C. Immunosuppressive effects of opioids-clinical relevance. J Neuroimmune Pharmacol. 2011;6:490-502.
50. Reiche EMV, Nunes SOV, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol. 2004;5:617-25.
51. Armstrong LJ, Heath VL, Sanderson S, Kaur S, Beesley JF, Herbert JM, Legg JA, Poulsom R, Bicknell R. ECSM2, an endothelial specific filamin a binding protein that mediates chemotaxis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1640-6.
52. Crampton SP, Davis J, Hughes CCW. Isolation of human umbilical vein endothelial cells (HUVEC). J Vis Exp. 2007;:183-3.
53. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Meth. 2012;9:671-5.